Preprint icon

Preprint

Bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until the age of six months: assessment of a United Kingdom-wide national vaccination programme

Abstract:
Background:
In late summer 2024, the United Kingdom (UK) introduced the maternal bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine for all pregnant individuals at a gestation of 28 weeks or more. After an initial catch-up phase, the maternal RSVpreF programme transitioned to year-round delivery, and in late summer 2025 nirsevimab replaced palivizumab for UK infants at high risk of severe RSV disease. We aimed to estimate the protection provided by m... Expand abstract
Publication status:
Published
Peer review status:
Not peer reviewed

Actions

Access Document

Preprint server copy:
10.2139/ssrn.6327706

Authors

More by this author
Role:
Author
ORCID:
0000-0002-4883-4202
More by this author
Role:
Author
ORCID:
0000-0001-7342-251X
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Research group:
Oxford Vaccine Group
Role:
Author
ORCID:
0000-0002-6350-6557
More by this author
Role:
Author
ORCID:
0000-0001-9244-9961

Contributors


More from this funder
Funder identifier:
https://ror.org/03ek62e72
Grant:
EAT/5815/25
More from this funder
Funder identifier:
https://ror.org/029chgv08
Grant:
WT 13600061
More from this funder
Funder identifier:
https://ror.org/0187kwz08
Grant:
NIHR207417
More from this funder
Funder identifier:
https://ror.org/02tdmfk69
Grant:
I-2526-300
More from this funder
Funder identifier:
https://ror.org/041kmwe10


Preprint server:
SSRN
Publication date:
2026-03-04
DOI:
Server owner:
Elsevier


Language:
English
Pubs id:
2385042
Local pid:
pubs:2385042
Source identifiers:
W7133482016
Deposit date:
2026-06-17
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP